The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study

Zhao, Y; Wu, L; Lu, Q; Gao, X; Zhu, X; Yao, X; Li, L; Li, W; Ding, Y; Song, Z; Liu, L; Dang, N; Zhang, C; Liu, X; Gu, J; Wang, J; Geng, S; Liu, Q; Guo, Y; Dong, L; Su, H; Bai, L; O'Malley, JT; Luo, J; Laws, E; Mannent, L; Ruddy, M; Amin, N; Bansal, A; Ota, T; Wang, M; Zhang, J

Zhang, J (通讯作者)，Peking Univ Peoples Hosp, Beijing, Peoples R China.

BRITISH JOURNAL OF DERMATOLOGY, 2022; 186 (4): 633

Abstract

Background Dupilumab is an antibody against interleukin-4 receptor alpha, used in the treatment of atopic dermatitis (AD). Objectives To evaluate the ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索